Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AD-MCI Clear all
Enrolling by invitation Not applicable Interventional

Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers

NCT07646054
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
Interventions
Education
Behavioral
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
60 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 8:00 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Lecanemab IV, Placebo, Lecanemab SC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
112
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 8:00 AM EDT
Recruiting Not applicable Interventional

δ in Dementia Clinical Trials

NCT05592678
View directory record Official record
Conditions
Alzheimer's Disease (AD), Dementia, Cognitive Decline, Mild Cognitivie Impairment (MCI)
Interventions
Donepezil
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 8:00 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

NCT02624778
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3002813, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 25, 2026, 8:00 AM EDT
Active, not recruiting No phase listed Observational

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

NCT02951598
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Florbetapir F 18 PET Scan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
77
States / cities
Anaheim, California • Imperial, California • Irvine, California + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 25, 2026, 8:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

NCT00908999
View directory record Official record
Conditions
Anosognosia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2011 · Synced Oct 25, 2026, 8:00 AM EDT
Terminated Phase 2 Interventional Results available

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

NCT04795466
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Canakinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 25, 2026, 8:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

NCT06584357
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection, MK6240
Other · Radiation
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
22
States / cities
Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 25, 2026, 8:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Combating Alzheimer's Through Sleep and Exercise

NCT04855630
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment (MCI), Cognitively Unimpaired, Alzheimer's Dementia (AD)
Interventions
Elemind Neuromodulation Headband, Exercise Routine
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 25, 2026, 8:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Integrative Therapy for Holistic, Natural Cognition and Lifestyle Rehabilitation

NCT04284449
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
Whole-practice cognitive optimization
Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
60 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 25, 2026, 8:00 AM EDT
Not listed Phase 1 Interventional

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

NCT04500847
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Moderate Dementia
Interventions
Emtriva Capsule, Placebo
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
50 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 25, 2026, 8:00 AM EDT
Completed Phase 1 Interventional

Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

NCT02221622
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Allopregnanolone injection (intravenous solution), Placebo injection (intravenous solution)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 25, 2026, 8:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

NCT05881239
View directory record Official record
Conditions
Subjective Cognitive Concerns, Mild Cognitive Impairment, Mild Behavioral Impairment, Healthy Aging
Interventions
AROMHA Brain Health Test
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 25, 2026, 8:00 AM EDT
Recruiting Not applicable Interventional

Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study

NCT07224607
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Photobiomodulation
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
55 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 8:00 AM EDT
Enrolling by invitation Not applicable Interventional

Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

NCT06245031
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild, Dementia Moderate, Dementia Alzheimers, Dementia of Alzheimer Type, AD
Interventions
Sensory Stimulation System (GS120) - Active
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years to 92 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
53
States / cities
Phoenix, Arizona • Sun City, Arizona • Anaheim, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 25, 2026, 8:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Predicting Pre-dementia

NCT07516119
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
Interventions
Not listed
Lead sponsor
Prevention Research Consortium Corp.
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 8:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prevention of Depression in Spouses of People With Cognitive Impairment

NCT00321971
View directory record Official record
Conditions
Depression
Interventions
PST-MCI/AD Caregiving, NT-MCI/AD Caregiving
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 25, 2026, 8:00 AM EDT
Completed Not applicable Interventional

Deep Brain Stimulation with LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease

NCT03347084
View directory record Official record
Conditions
Brain Imaging, Mild Cognitive Impairment, Alzheimer Disease, Deep Brain Stimulation
Interventions
Excitation, Inhibition
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 25, 2026, 8:00 AM EDT
Enrolling by invitation No phase listed Observational

Expanding Access to Cognitive Health Biomarker Testing at Home

NCT07594665
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Dementia (AD), Subjective Cognitive Decline (SCD), Cognitive Aging
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 25, 2026, 8:00 AM EDT
Active, not recruiting Phase 2 Interventional

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

NCT04685590
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Dasatinib + Quercetin, Placebo Capsules
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 25, 2026, 8:00 AM EDT
Terminated Phase 2 Interventional Results available

Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

NCT02503501
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Interventions
Insulin glulisine, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 25, 2026, 8:00 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

NCT04141150
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
Interventions
[18F]APN-1607
Drug
Lead sponsor
APRINOIA Therapeutics, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
New Haven, Connecticut • Mount Arlington, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 25, 2026, 8:00 AM EDT
Recruiting Not applicable Interventional

Music Therapy for Patients With Alzheimer's Disease

NCT05151562
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Virtual Music Therapy
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 8:00 AM EDT
Not yet recruiting Phase 2 Interventional

Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

NCT07756294
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Empagliflozin, Insulin, Insulin Placebo, Empagliflozin Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 8:00 AM EDT